Plus, news about KalVista, Kaken Pharmaceutical, Lyell and Tango Therapeutics:
Rallybio stops work on RLYB212: The company had been testing the drug to see if it could prevent fetal and neonatal alloimmune thrombocytopenia, which occurs ...
↧
